À propos
Senior biotechnology executive with more than 15 years of experience in business…
Articles de Marjorie
Activité
2 k abonnés
-
Marjorie Sidhoum a republié ceciMarjorie Sidhoum a republié ceciThe #Obesity & GPCR session at Discovery on Target reinforced just how quickly obesity #DrugDevelopment is evolving. The discussion is no longer solely about identifying the next effective target. It is increasingly about how clinically validated GPCR pathways regulating food intake and energy balance can be modulated more precisely to improve efficacy, durability, tolerability and long-term patient outcomes. With the increasing success of #GLP1-based and, more broadly, incretin-based therapies, interest in other GPCRs with similar anti-obesity potential is real across the pharma industry. The field is clearly moving toward precision GPCR pharmacology and next-generation therapeutic designs that seek to address broader patient populations and more diverse disease biology. In this context, I was pleased to disclose, for the first time, our MC4R-BAPC (Biased Agonist PharmacoChaperone) program and share our perspective on how #PrecisionPharmacology may help unlock the full potential of MC4R across both common and MC4R mutation-associated obesity. At Kainova Therapeutics, in #Collaboration with Prof. Michel Bouvier’s lab Université de Montréal, our MC4R-BAPC series was designed with that ambition in mind. It combines a unique set of three complementary properties: dual MC4R/MC3R activity, functional bias against β-arrestin signaling, and pharmacochaperone activity to boost membrane trafficking of wild type and mutant receptors, all within a single molecule. Preclinical data from DIO and humanized MC4R knock-in models support the therapeutic promise of this three-layer design. Thank you to everyone who joined the session and contributed to the discussion. It was a pleasure to exchange perspectives on next generation GPCR drug design and the future of obesity therapeutics. I look forward to continuing the conversation and discussing potential #PartneringOpportunities. #BusinessDevelopment #DiscoveryOnTarget
-
Marjorie Sidhoum a partagé ceciI’m excited to be attending Optimum’s 18th Annual Healthcare Investor Conference! It’s set to be a fantastic opportunity to share ideas, make new connections and stay close to the conversations shaping the healthcare sector. Looking forward to seeing everyone there! Kainova Therapeutics #Healthcare #LifeSciences #Optimumconference2026
-
Marjorie Sidhoum a republié ceciMarjorie Sidhoum a republié ceciNext week at Discovery on Target in Boston, Stephan Schann, our CSO, and Laurent Sabbagh, Ph.D., our VP of Research will present two highly differentiated programs illustrating how Kainova Therapeutics is advancing precision GPCR modulation across therapeutic areas. In #ImmunoOncology, the field is increasingly focusing on remodeling the tumor microenvironment, with Treg depletion gaining momentum as a strategy to overcome immune suppression and improve anti-tumor responses. Don’t miss Laurent’s presentation on: ➡️ 29 September 2026 I 8:35 AM EDT During the « Antibodies Against Challenging Targets » session, Laurent will present DT-7012, our Treg depleting anti-CCR8 antibody engineered for optimized binding and Fc-enhanced ADCC/ADCP to selectively deplete CCR8+ tumor-resident Tregs while preserving peripheral immune integrity. The presentation will highlight DT-7012’s key differentiators, namely its unique activity in high-CCL1 TME and boosted ADCC/ADCP activity. The program is currently progressing through the DOMISOL Phase I/II trial in advanced solid tumors in France and Australia. In #Obesity, as innovation moves beyond GLP-1 therapies alone, our approach focuses on precision pharmacology targeting the Melanocortin Receptor 4 (MC4R). Our CSO will take the floor on: ➡️ 30 September 2026 I 12:20 PM EDT During the "Leading Generation trategies (Obesity & GPCRs » session, Stephan will disclose, for the first time, our MC4R-BAPC (Biased Agonist PharmacoChaperone) program, an orally available small molecule MC4R modulator designed to address both wild type and MC4R mutation-associated obesity. Rather than simply activating MC4R, this next-generation approach combines dual MC4R/MC3R activity, functional bias against β-arrestin signaling to sustain receptor signaling and pharmacochaperone activity to boost membrane trafficking of wild type and mutant receptors. Lead compound have demonstrated sustained reductions in food intake and weight gain across DIO and humanized MC4R knock-in models, supporting the promise of this three-layer design. If you are attending #DiscoveryOnTarget, we would be delighted to connect and discuss next-gen GPCR drug design, precision pharmacology and new opportunities to address patient populations with significant unmet and underserved needs. See you in Boston! #DrugDevelopment #ClinicalDevelopment #CCR8 #MC4R #PartneringOpportunities
-
Marjorie Sidhoum a partagé ceciYou will be at Discovery on Target end of the month? Save the date! Don't miss the chance to learn more about our MC4R Biased Agonist PharmacoChaperone small molecules for obesity and genetic-based rare obesity syndromes.Marjorie Sidhoum a partagé ceciWhile #Obesity is driving greater than ever strategic importance for both pharma industry and growing populations, I’m excited to attend Discovery on Target conference to disclose, for the first time, our MC4R-BAPC (Biased Agonist PharmacoChaperone) program. Kainova Therapeutics has discovered the next generation of Melanocortin Receptor 4 modulator designed to advance innovation and bring a differentiated therapeutic solution to patients suffering from obesity. 📍 Boston, MA 🗓️ Wednesday, September 30 at 9:05 AM EDT Today, the conversation in #DrugDevelopment is shifting from whether MC4R works to how precision pharmacology can unlock its full therapeutic potential across broader patient populations. MC4 receptor is a clinically validated GPCR target with a central role in regulating food intake and energy expenditure, yet it remains addressed almost exclusively through biologics and with standard pharmacology. At Kainova Therapeutics, we have the ambition to address both general and genetic/rare obesity syndromes. During my presentation, I’ll share how our MC4R-BAPC series combines a unique set of three properties within a single orally available small molecule: ✅ Dual MC4R/MC3R activity, which is key to maximize therapeutic efficacy, as only this dual approach has generated positive clinical data ✅ Functional bias against β-arrestin signaling to prevent receptor internalization and sustain receptor activation ✅ Pharmacochaperone activity to boost membrane trafficking, a property that is not only beneficial in reversing the mutated MC4 receptor at the cell surface in case of mistrafficking in MC4R mutation-associated obesity, but it also supports an increased surface expression of wild-type receptors in general obesity. This three-layer design is intended to address key limitations that have constrained previous MC4R approaches, while creating opportunities in both common and MC4R mutation-associated obesity. Our lead compounds have demonstrated sustained reductions in food intake and weight gain in DIO rodent models and humanized genetic MC4R knock-in models, supporting the therapeutic promise of this approach. If you’ll be at #DiscoveryOnTarget, I’d be glad to connect and discuss next-gen GPCR design and precision #GPCRModulation strategies. Let’s talk in Boston. #DrugDevelopment #PartneringOpportunities #BusinessDevelopment
-
Marjorie Sidhoum a republié ceciMarjorie Sidhoum a republié ceci🏆 We are proud to share that Kainova Therapeutics has been nominated as a finalist for ‘Series B Raise of the Year’ at the 2026 LSX European Lifestars Awards - Celebrating Life Science Leaders In a highly selective #BiotechFinancing environment, being shortlisted is a meaningful recognition of the progress enabled by our #SeriesB financing and the confidence our investors have placed in our vision. Led by Investissement Québec with continued support from a committed group of European and global healthcare investors including CTI Life Sciences Fund Panacea Capital 3B Future Health Fund I & II Seventure Partners Viva BioInnovator Turenne Groupe Schroders Capital adMare BioInnovations Seido Capital, the financing has enabled important clinical progress for DT-7012 and positioned us for the next stage of growth. DT-7012, our Treg depleting ADCC/ADCP competent anti-CCR8 antibody, is now being evaluated in the DOMISOL Phase I/II trial in advanced solid tumors. Following the initiation of the study in Australia, the trial expanded into Europe with the first patient dosed in France. Being shortlisted among nine finalists is both a recognition of the commitment of our employees, investors, collaborators, and a strong external validation of our strategy, our progress and the impact this financing has had on our evolution as a global clinical-stage biotech advancing differentiated GPCR-modulating therapies for patients. Thank you to everyone who continues to support our mission. The Gold, Silver and Bronze winners will be announced at the awards ceremony in London on 16 November. We look forward to celebrating with fellow finalists and industry peers 🎉 Keep your fingers crossed 🤞 #ClinicalDevelopment #HealthcareInnovation #LifeSciences #LifestarsAwards Informa Connect
-
Marjorie Sidhoum a partagé ceciA great overview of the discovery of DT-9081, our EP4R antagonist candidate dedicated to reverse PGE2-mediated immunosuppression in solid tumors. Kudos to colleagues who contributed to this work!Marjorie Sidhoum a partagé ceciA couple of days after the brilliant presentation of my colleague Anne-Laure Blayo at EFMC - European Federation for Medicinal Chemistry and Chemical Biology International Symposium 2026 on the discovery and early clinical progress of DT-9081, I’m excited to share that our new article on DT-9081 is now published in the #JMEDCHEM. DT-9081 is a potent and orally bioavailable small molecule antagonist of the EP4 receptor for the treatment of solid cancers. Why focus on EP4R in solid tumors? The COX-2/PGE2/EP4R axis is a key driver of immunosuppression and enables tumors to evade immune surveillance, a mechanism that continues to limit the effectiveness of current standard of care. The central question has always been whether we can design an asset that meaningfully shifts this biology in patients. DT-9081 is our answer to that question. The new article describes its discovery and optimization as an oral EP4R antagonist. Today, DT-9081 is supported by Phase I data and a consistent biomarker package demonstrating sustained EP4 receptor engagement, robust PK/PD characteristics, a favorable safety profile and early signs of anti-tumor activity in solid cancers. This publication also comes at a timely moment. Encouraging Phase II updates from ONO PHARMACEUTICAL CO., LTD. with an EP4R antagonist plus anti-PD1 in gastric/GEJ cancer, disclosed at American Society of Clinical Oncology (ASCO) this year, further strengthen the clinical case for targeting the EP4 pathway. For those working in this space, it is an exciting time to discuss where EP4R fits within next-gen #ImmunoOncology strategies. A sincere thank you to our outstanding collaborators at Kainova Therapeutics Anne-Laure Blayo Gael Hommet Mickaël FER Luc B.ER Luc B. Edith STEINBERG Thomas Maurin Christel Franchet Stanislas Mayer and everyone who contributed to this work. #DrugDevelopment #ClinicalDevelopment #CancerResearchPublication ACS Publications
-
Marjorie Sidhoum a partagé ceciKudos to my colleague Anne-Laure Blayo who made a brilliant oral presentation at European Federation of Medicinal Chemistry in Basel giving an overview of the discovery behind our DT-9081 candidate, a phase II ready EP4 antagonist. More coming soon...Marjorie Sidhoum a partagé ceciLive from @EFMC - European Federation for Medicinal Chemistry and Chemical Biology International Symposium 2026 in Basel, Switzerland. It was a pleasure to share the discovery and development work behind DT-9081, our orally available EP4 receptor antagonist, designed to counter PGE2-driven immunosuppression in solid tumors, a well-recognized mechanism contributing to immunotherapy resistance. I especially appreciated the thoughtful discussions around our platform, our expertise in translating GPCR biology, and the integrated discovery-to-clinic approach behind our differentiated oral small molecule with sustained EP4 receptor engagement, robust PK/PD characteristics, favorable safety profile and early signs of anti-tumor activity. This week also marks another milestone with the publication of our article on DT-9081 in the Journal of Medicinal Chemistry. The manuscript further expands on the work presented today, highlighting the potential of DT-9081 to synergize with #Immunotherapy and/or chemotherapy to support stronger antitumor responses. Having this work presented at EFMC and published in the same week is a proud moment for all of us at @Kainova Therapeutics. As EFMC was a great opportunity to connect around a wide range of #DrugDiscovery topics, highlighting continued interest in GPCR-modulating strategies, don’t miss another rendez-vous later this month at @Discovery on Target in Boston, where our VP of Research @Laurent Sabbagh will provide an update on DT-7012, our Treg-depleting ADCC/ADCP competent anti-CCR8 antibody, and our CSO @Stephan Schann will discuss MC4R and next-gen GPCR modulation. If you are in Basel and want to dive deeper into #GPCRInnovation and the science behind smarter #DrugDevelopment, I would be happy to connect and continue the conversation 1:1. #Networking #GPCR
-
Marjorie Sidhoum a republié ceciMarjorie Sidhoum a republié ceciI’m excited to share that I’ll be speaking at the EFMC - European Federation for Medicinal Chemistry and Chemical Biology International Symposium 2026: 📍Basel, Switzerland 🗓️ 8 September at 13:50 PM I’ll be presenting the discovery of DT-9081, our clinical candidate EP4 receptor antagonist orally available designed to counter PGE2-driven immunosuppression in solid tumors. EP4 antagonism is gaining momentum in #ImmunoOncology with recent positive clinical data from counterpart disclosed at American Society of Clinical Oncology (ASCO) this year, and DT-9081 is a great example of how we approach mechanism-driven drug design at Kainova Therapeutics. What began as a hypothesis that we could turn the COX-2 / PGE2 / EP4 immunosuppressive axis into an opportunity for patients who don’t respond to current immunotherapies, became a coordinated effort across #MedicinalChemistry, DMPK, toxicology, CMC and #TranslationalScience. Together, we shaped an oral small molecule with sustained EP4 receptor engagement, robust PK/PD characteristics, favorable safety profile and early signs of anti-tumor activity. DT-9081 reflects the deep biological knowledge and scientific rigor behind our integrated discovery-to-clinic approach, it illustrates how GPCR-modulating strategies can unlock new therapeutic options for cancer patients. If you are at EFMC, come say hello. I would be happy to connect and discuss the science driving smarter, mechanism-driven #DrugDevelopment. #Networking #GPCR
-
Marjorie Sidhoum a partagé ceciSupport to all those affected by mega fires and who have been displaced to escape the threat.Marjorie Sidhoum a partagé ceciStanding with Our Communities in France and Canada At Kainova Therapeutics, we are deeply saddened by the devastating wildfires affecting communities in both France and Canada. As a company with roots in both countries, these events resonate with us in a particularly meaningful way. Today, our thoughts are with the individuals, families, colleagues, collaborators, partners, and friends who are facing uncertainty and disruption as a result of these fires. From the Bordeaux region to the vast territories of Canada, communities are confronting the destructive consequences of wildfire seasons of growing intensity. Behind every headline are people whose lives, homes, businesses, and natural environments are being profoundly affected. We also recognize the extraordinary efforts of firefighters, emergency responders, volunteers, and local authorities who continue to work tirelessly to protect lives and communities under difficult and often dangerous conditions. These fires remind us of something larger than any single region or country. While each wildfire has its own causes and circumstances, the increasing frequency and severity of extreme weather events around the world highlight the challenges posed by a changing climate. The impacts of climate change are no longer distant or abstract. They are being felt by our communities, our families, and our ecosystems. They affect the places where we live, work, and build our futures. This reality calls for a collective awareness and a shared sense of responsibility. Addressing climate change is not the responsibility of governments alone, nor of businesses alone, nor of individuals acting in isolation. It is a challenge that belongs to all of us and requires collective commitment, innovation, and action. As a scientific community, we are especially conscious of the importance of evidence, collaboration, and long-term thinking. The same principles must guide our efforts to protect the environment and strengthen the resilience of our societies for future generations. Today, we stand in solidarity with all those affected by these fires in France, Canada and beyond. We extend our heartfelt support to our collaborators, partners, their families and all these populations, and we hope for the safety of everyone impacted, the swift containment of the fires, and the recovery of the communities affected. May these difficult moments strengthen not only our compassion for one another, but also our collective determination to build a more sustainable future. #Wildfires #France #Canada #ClimateAction #ClimateAwareness #Sustainability #Solidarity #Resilience #Community #TogetherForTomorrow #KainovaTherapeutics
-
Marjorie Sidhoum a aimé ceciMarjorie Sidhoum a aimé ceciThe #Obesity & GPCR session at Discovery on Target reinforced just how quickly obesity #DrugDevelopment is evolving. The discussion is no longer solely about identifying the next effective target. It is increasingly about how clinically validated GPCR pathways regulating food intake and energy balance can be modulated more precisely to improve efficacy, durability, tolerability and long-term patient outcomes. With the increasing success of #GLP1-based and, more broadly, incretin-based therapies, interest in other GPCRs with similar anti-obesity potential is real across the pharma industry. The field is clearly moving toward precision GPCR pharmacology and next-generation therapeutic designs that seek to address broader patient populations and more diverse disease biology. In this context, I was pleased to disclose, for the first time, our MC4R-BAPC (Biased Agonist PharmacoChaperone) program and share our perspective on how #PrecisionPharmacology may help unlock the full potential of MC4R across both common and MC4R mutation-associated obesity. At Kainova Therapeutics, in #Collaboration with Prof. Michel Bouvier’s lab Université de Montréal, our MC4R-BAPC series was designed with that ambition in mind. It combines a unique set of three complementary properties: dual MC4R/MC3R activity, functional bias against β-arrestin signaling, and pharmacochaperone activity to boost membrane trafficking of wild type and mutant receptors, all within a single molecule. Preclinical data from DIO and humanized MC4R knock-in models support the therapeutic promise of this three-layer design. Thank you to everyone who joined the session and contributed to the discussion. It was a pleasure to exchange perspectives on next generation GPCR drug design and the future of obesity therapeutics. I look forward to continuing the conversation and discussing potential #PartneringOpportunities. #BusinessDevelopment #DiscoveryOnTarget
-
Marjorie Sidhoum a réagi à ceciMarjorie Sidhoum a réagi à ceciElkedonia une nouvelle piste pour les dépressions résistantes. Basée à Strasbourg, la biotech franco-belge Elkedonia développe une approche thérapeutique inédite pour les personnes souffrant de dépression résistante, c’est-à-dire celles qui ne répondent pas ou insuffisamment aux antidépresseurs classiques. Son ambition est de concevoir un médicament « first-in-class » capable d’agir non plus principalement au niveau des synapses, mais à l’intérieur même des neurones, sur un mécanisme biologique associé à la capacité du cerveau à s’adapter et à se réparer : la neuroplasticité. Au centre de ce programme se trouve ELK1, une protéine intracellulaire impliquée dans les circuits neuronaux liés à l’humeur et longtemps considérée comme difficile à cibler par un médicament. Elkedonia cherche à identifier des molécules neuroplastogènes capables d’inhiber cette protéine de manière sélective, avec l’objectif d’obtenir un effet rapide tout en évitant les effets indésirables parfois associés à la kétamine ou aux psychédéliques, tels que la dissociation, les hallucinations ou le risque de dépendance. L’entreprise, qui a levé 11,25 millions d’euros en amorçage, reste à un stade préclinique : elle dispose d’une cible validée et d’outils pharmacologiques, mais doit encore sélectionner puis optimiser sa molécule‑médicament. Une entrée en clinique est envisagée autour de 2029, avant une première étude chez des patients au début des années 2030, ce qui rappelle le temps long et les exigences de développement propres à la biotech. Si cette voie aboutit, Elkedonia pourrait élargir les options pour des patients aujourd’hui confrontés à un besoin thérapeutique majeur, en visant notamment un traitement oral, administrable à domicile et potentiellement accessible aussi aux adolescents et aux personnes âgées. Delphine Charvin, PDG et cofondatrice de l'entreprise en 2025 avec Mélanie Rouillier, directrice des opérations. (Photo Peter Allan)
-
Marjorie Sidhoum a réagi à ceciMarjorie Sidhoum a réagi à ceciWe've closed Sofinnova Partners MD Start IV at €82 million. Oversubscribed, and ready to invest in six to eight new medtech companies over the next five years. Our approach is rooted in partnership with clinicians and scientists. We work alongside founders from inception, providing capital, clinical insight, and operational support through key development stages. The previous Sofinnova MD Start fund backed six companies that have collectively raised over €140 million in follow-on financing. Among them: 🔹LimFlow (acquired by Inari Medical) 🔹Moon Surgical (FDA and CE Mark clearance, now used to treat over 3,700 patients) 🔹CorWave (€100 million raised). We're ready to build the next generation of medtech 🙌 .
-
Marjorie Sidhoum a réagi à ceciMarjorie Sidhoum a réagi à ceciNext week at Discovery on Target in Boston, Stephan Schann, our CSO, and Laurent Sabbagh, Ph.D., our VP of Research will present two highly differentiated programs illustrating how Kainova Therapeutics is advancing precision GPCR modulation across therapeutic areas. In #ImmunoOncology, the field is increasingly focusing on remodeling the tumor microenvironment, with Treg depletion gaining momentum as a strategy to overcome immune suppression and improve anti-tumor responses. Don’t miss Laurent’s presentation on: ➡️ 29 September 2026 I 8:35 AM EDT During the « Antibodies Against Challenging Targets » session, Laurent will present DT-7012, our Treg depleting anti-CCR8 antibody engineered for optimized binding and Fc-enhanced ADCC/ADCP to selectively deplete CCR8+ tumor-resident Tregs while preserving peripheral immune integrity. The presentation will highlight DT-7012’s key differentiators, namely its unique activity in high-CCL1 TME and boosted ADCC/ADCP activity. The program is currently progressing through the DOMISOL Phase I/II trial in advanced solid tumors in France and Australia. In #Obesity, as innovation moves beyond GLP-1 therapies alone, our approach focuses on precision pharmacology targeting the Melanocortin Receptor 4 (MC4R). Our CSO will take the floor on: ➡️ 30 September 2026 I 12:20 PM EDT During the "Leading Generation trategies (Obesity & GPCRs » session, Stephan will disclose, for the first time, our MC4R-BAPC (Biased Agonist PharmacoChaperone) program, an orally available small molecule MC4R modulator designed to address both wild type and MC4R mutation-associated obesity. Rather than simply activating MC4R, this next-generation approach combines dual MC4R/MC3R activity, functional bias against β-arrestin signaling to sustain receptor signaling and pharmacochaperone activity to boost membrane trafficking of wild type and mutant receptors. Lead compound have demonstrated sustained reductions in food intake and weight gain across DIO and humanized MC4R knock-in models, supporting the promise of this three-layer design. If you are attending #DiscoveryOnTarget, we would be delighted to connect and discuss next-gen GPCR drug design, precision pharmacology and new opportunities to address patient populations with significant unmet and underserved needs. See you in Boston! #DrugDevelopment #ClinicalDevelopment #CCR8 #MC4R #PartneringOpportunities
-
Marjorie Sidhoum a réagi à ceciMarjorie Sidhoum a réagi à ceciSemaine de rentrée ! Semaine de découverte… semaine de rencontre avec des nouveaux visages et quelques anciens… une nouvelle histoire à écrire dans la belle maison Palatine! Un énorme merci à tous ceux qui se sont mis en quatre pour m’accueillir! Je crois… que je vais me sentir bien ici aussi! Il me reste encore à retrouver l’équilibre après autant de changements, mais j’ai hâte de retrouver le terrain économique local et de faire rayonner la maison sur la place alsacienne. À très vite! 😘
-
Marjorie Sidhoum a réagi à ceciMarjorie Sidhoum a réagi à ceciToday marks the end of an era, as it was my last day as a full-time member of the team at Crossbow Therapeutics, Inc. I'm deeply grateful for the last five years - for the opportunity to help build this company, for everything I had the chance to take on and learn, and most of all, for the people I was lucky enough to work with along the way. It's been one of the most formative and gratifying experiences of my professional life to date. It is incredible to think that when Patrick Baeuerle, Todd Foley and I founded the company in the fall of 2021, all we had was an idea, and that now, Crossbow has 2 molecules being tested in patients, and multiple other molecules on their way to the clinic. The efficiency and effectiveness of this team is truly inspiring. While it was a difficult decision to move on, I know the company is in great hands, under Briggs Morrison's leadership. I'll remain available as an advisor to the company, but am also excited to dive into my next adventure - more on that soon!
Expérience et formation
Autres profils similaires
Découvrir plus de posts
-
Maximilien Vermandel
[#PressRelease] Hemerion Therapeutics reaches a new milestone in its international clinical development 🚀 We have just opened a new clinical investigation site at Lille University Hospital (CHU de Lille) to advance the Phase 1/2 evaluation of our Pentalafen® / Heliance® therapy for #glioblastoma. Together with our U.S. site at UPMC University of Pittsburgh Neurosurgery with Pr Costas Hadjipanayis, this expansion strengthens our ability to accelerate patient enrollment and conduct our clinical program across both Europe and the United States — demonstrating that our technology and development strategy are fully compatible with European and U.S. regulatory pathways. 🌍 The Lille team has now enrolled the last patients of the second cohort, enabling the initiation of the DSMB review — a key step as we prepare for future pivotal discussions with the EMA and FDA. 📈 My sincere thanks to Dr. VAULEON ENORA ANNIE, Prof. Nicolas REYNS, and all our clinical partners for their exceptional commitment. 🙏 ➡️ Full press release below. La Voix du Nord Les Echos Le Journal des Entreprises Maddyness BIOTECHFINANCES CFNEWS Eco121 Eurasanté Inserm Nord Ouest Neighborhood: The Healthtech Innovation Program by VCLS Finovam Gestion CAPTECH Santé SATT Nord University of Lille 1 Sciences and Technology Capital Cell BioLabs France BioLabs Ipsen FINORPA Society for Neuro-Oncology ICOSA France Biotech French Healthcare Business France North America The Brain Tumour Charity National Brain Tumor Society #HealthTech #ClinicalResearch #NeuroOncology #HemerionTherapeutics #Innovation
8 commentaires -
CASSS – Sharing Science Solutions
We’re excited to announce a new collaboration between CASSS and the IQ Consortium. This year, representatives from the IQ Biologics CMC Leadership Group served as liaisons on the Scientific Organizing Committee bringing deep industry insight and subject-matter expertise to forum planning. This collaboration directly informed the development of Workshop II – Right Dose, Real Impact: Strategies to Ensure Consistent Dose for Every Patient, which features the work of the IQ Consortium Injectable Products Allowable Content Working Group. Together, CASSS and IQ are strengthening dialogue across industry, regulators, and standards organizations, enhancing the scientific rigor and relevance of forum content, with a shared commitment to continued collaboration in future forums. #CASSS #IQConsortium #CMC #CMCNA2026 #Injectables #DrugProductQuality #StrategyForum #IndustryCollaboration
1 commentaire -
David Leroux-Petersen
Rottendorf Pharma brings decades of experience in late-stage development, scale-up and commercial manufacturing of oral solid dosage forms. Through this collaboration, we provide our biotech clients a continuous transition from early-stage development to commercial supply, with seamless knowledge transfer. #CorealisPharma
-
Sebastian BioPharma
Extending TAP-targeted neoantigen induction beyond oncology Sebastian BioPharma is proud to announce the publication of our new study in The Journal of Infectious Diseases https://lnkd.in/eQgKmKee, demonstrating that our iTAP neoantigen-induction concept—originally developed to enhance tumor immunity—also applies to infectious diseases. We show that HIV-, CMV-, and EBV-infected cells with reduced TAP expression—whether naturally occurring or experimentally induced using our antibody-oligonucleotide conjugate platform—present the same cryptic neoantigens previously identified in TAP-low tumor cells. CD8⁺ T cells stimulated against these antigens effectively recognize and eliminate the infected cells. This work highlights that the iTAP concept enables a unified immune response spanning oncology and infectious disease, bypassing pathogen-specific antigen discovery and overcoming antigenic heterogeneity. Our antibody-oligonucleotide conjugate platform, now used to implement iTAP in vivo, demonstrates how precise manipulation of TAP expression can form the basis of a broadly applicable therapeutic strategy capable of targeting most tumors or pathogen-infected cells in which TAP is downregulated. More to come as we continue advancing this transformative concept.
1 commentaire